This article was originally published in The Gray Sheet
Begins trading on the NASDAQ market following the acquisition of Diagnostics Holding Corporation's outstanding stock in exchange for approximately 1.2 mil. shares of Endogen common stock. As a result of the transaction, the manufacturer of research products and immunoassay test kits adds to its cash reserves $3.1 mil. that DHC possessed at the time of the transaction. Endogen says in a March 19 release that the DHC purchase allows the firm "to accelerate...internal growth and to pursue possible acquisitions of companies or product lines in the research products and niche diagnostics fields." DHC was formed as part of a reorganization involving Recordati and Recordati's majority- owned subsidiary, Leeco Diagnostics ("The Gray Sheet" Dec. 21, p. 16). As a result of the merger with Endogen, Leeco shareholders other than Recordati own approximately 47% of outstanding Endogen common shares, which total approximately 2.6 mil.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.